NeuroPace (NPCE) Q2 FY26 earnings call

NeuroPace delivered robust Q2 FY26 results, driven by strong 21% growth in its core RNS System business, consistent with its long-term framework. While the IGE PMA supplement faced a setback, management expressed confidence in a path towards approval through the SIR process. The company continues to invest in product development, including the launch of ECOG Assistant and remote care capabilities, while maintaining financial discipline and improving its full-year adjusted EBITDA outlook.